Clinical Trial Update: Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing single-agent belantamab mafodotin to pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma; sponsor GlaxoSmit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-06